Clozapine ANC monitoring tracker
Enter the clozapine start date. The tool generates the ANC monitoring schedule from the FDA prescribing information: weekly for the first six months, every two weeks for months six through twelve, then monthly indefinitely. The mandatory REMS program ended February 24, 2025, but ANC monitoring per the label remains the standard of care.
ANC monitoring schedule
Enter a start date to generate the schedule.
Reference data current as of June 8, 2026. Sources: FDA Prescribing Information for clozapine (via DailyMed); FDA Drug Safety Communication, February 24, 2025 (elimination of the mandatory REMS program); American Association of Psychiatric Pharmacists Clozapine in Practice guidance.
How to read this
The schedule shown reflects the standard-of-care monitoring cadence in the FDA label. The REMS program ended in February 2025, so lab results no longer need to be entered into a national registry to obtain the medication. The monitoring itself did not go away. Any deviation from the cadence, including tighter monitoring after a lab result close to threshold, is a decision for the treating clinician.
Discontinue thresholds per label: ANC below 1.0 x 10^9/L in the standard population, or below 0.5 x 10^9/L in patients with benign ethnic neutropenia. Hematology involvement is standard when ANC drops toward those thresholds.
About this tool
Clozapine is the only antipsychotic with evidence for treatment-resistant schizophrenia and one of the few with mortality-reduction data in real-world observational studies. It is also the antipsychotic with the most burdensome monitoring requirements: weekly ANC labs for the first six months, biweekly for months six through twelve, then monthly for the duration of treatment. This tool generates every date on the schedule from a user-entered start date.
The FDA eliminated the mandatory REMS program on February 24, 2025, ending the requirement to submit ANC results into a national registry and to complete prescriber and pharmacy certification. The label monitoring schedule itself remains unchanged. This tool reflects the post-REMS reality: the same clinical cadence, without the registry logistics. Missing the ANC monitoring or dosing outside the label schedule is not made safer by the REMS elimination.
The schedule accommodates benign ethnic neutropenia (BEN) and DARC-null status with the lower ANC threshold specified in the label (at least 1.0 x 10^9/L to continue, discontinue below 0.5 x 10^9/L). Selecting BEN status in the tool updates the threshold on the output.
The output also flags cardiac monitoring: baseline troponin, CRP, and ECG, with repeat at week 4 and clinical vigilance for tachycardia at rest, fever, chest pain, and shortness of breath during the first month. Clozapine-induced myocarditis is uncommon but potentially fatal, and it is the sort of thing that presents subtly in the first 4 to 8 weeks. The clozapine drug page covers the full presentation and management. Sources: FDA Prescribing Information for clozapine via DailyMed, FDA Drug Safety Communication February 24, 2025, American Association of Psychiatric Pharmacists Clozapine in Practice guidance.
Common questions
- What ended when the clozapine REMS program was eliminated in February 2025?
The mandatory Risk Evaluation and Mitigation Strategy (REMS) program for clozapine was eliminated on February 24, 2025. What ended: the requirement to submit ANC lab results into a national registry, prescriber and pharmacy certification, and dispensing restrictions tied to registry status. What did not end: the FDA label monitoring schedule itself. Weekly ANCs for the first six months, biweekly for months six through twelve, then monthly indefinitely remains the standard of care and the label recommendation. The elimination reduced logistical burden, not clinical vigilance.
- What is the ANC threshold for continuing clozapine?
Standard population: ANC of at least 1.5 x 10^9/L. Below 1.0 x 10^9/L, discontinue clozapine and consult hematology. For patients with benign ethnic neutropenia (BEN) or DARC-null status: threshold is at least 1.0 x 10^9/L, discontinue below 0.5 x 10^9/L. BEN is common in individuals of African, Middle Eastern, and West Indian descent and is not associated with increased infection risk. The lower threshold prevents unnecessary treatment discontinuation in this population.
- What is benign ethnic neutropenia (BEN)?
BEN is a normal variant of lower baseline neutrophil count (typically 1.0 to 1.5 x 10^9/L) most often seen in individuals of African, Middle Eastern, or West Indian descent, associated with the DARC-null genotype (ACKR1 gene). BEN carries no increased infection risk. Recognition of BEN is important because a patient with baseline BEN counts would otherwise fail standard clozapine monitoring thresholds despite having a normal baseline for their population. The label provides separate lower thresholds for BEN patients.
- Does clozapine require cardiac monitoring in addition to ANC?
Yes. Clozapine can cause myocarditis, most often in the first 4 to 8 weeks of treatment. Standard practice includes baseline troponin, CRP, and ECG, with repeat at week 4 and clinical vigilance for tachycardia at rest, fever, chest pain, and shortness of breath during the first month. Some centers extend this to weekly troponin and CRP for the first 4 weeks. Cardiac monitoring is not in the ANC schedule but is part of standard clozapine care. This tool flags it separately.
- What happens if ANC drops below threshold on clozapine?
Depends on grade. Mild neutropenia (ANC 1.0 to 1.5 x 10^9/L in standard population) typically triggers more frequent monitoring (twice weekly) with continuation of clozapine. Moderate neutropenia (ANC 0.5 to 1.0) means holding clozapine and daily ANC. Severe neutropenia or agranulocytosis (ANC below 0.5) means permanent discontinuation and hematology involvement. Decisions belong with the treating team.
- Can clozapine be restarted after a low ANC event?
Sometimes, with specific labeling. For dose interruption below 48 hours: restart at usual dose. For interruption 48 hours or longer: restart at 12.5 mg/day and re-titrate. For prior severe neutropenia or agranulocytosis: rechallenge is discouraged but has been reported successfully in some centers with intensive monitoring. Rechallenge is generally a decision for hematology and psychiatric pharmacology consultation rather than routine practice.